SSY Group (HKSE:02005) Cash And Cash Equivalents : HK$1,258 Mil (As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is SSY Group Cash And Cash Equivalents?

SSY Group's quarterly cash and cash equivalents declined from Dec. 2023 (HK$1,615.21 Mil) to Jun. 2024 (HK$1,564.54 Mil) but then stayed the same from Jun. 2024 (HK$1,564.54 Mil) to Dec. 2024 (HK$1,257.70 Mil).

SSY Group's annual cash and cash equivalents declined from Dec. 2022 (HK$1,667.55 Mil) to Dec. 2023 (HK$1,615.21 Mil) and declined from Dec. 2023 (HK$1,615.21 Mil) to Dec. 2024 (HK$1,257.70 Mil).

SSY Group Cash And Cash Equivalents Historical Data

The historical data trend for SSY Group's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SSY Group Cash And Cash Equivalents Chart

SSY Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

1,445.91

1,661.74

1,667.55

1,615.21

1,257.70

SSY Group Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															1,667.55	1,789.62	1,615.21	1,564.54	1,257.70

SSY Group Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

SSY Group (HKSE:02005) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

SSY Group Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of SSY Group's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

SSY Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » Cash And Cash Equivalents

Traded in Other Exchanges

N/A

Address

Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG

Website

http://www.ssygroup.com.hk

SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.

Executives

China Pharmaceutical Company Limited	2101 Beneficial owner
Qu Jiguang	2201 Interest of corporation controlled by you
Ubs Group Ag	2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si	2101 Beneficial owner

SSY Group Headlines

No Headlines